2025 Q4 -tulosraportti
Vain PDF
85 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sittenDo YOU have a link to an interview with Wiklund or one of the others in the company? Or a podcast? Please post it below here. It would be nice to get a lot of information under 1 and the same post here. Good to listen more than 1 time. See many are angry and frustrated these days. Find information about the company that the management itself releases, there have been several interviews and podcasts shared previously....... oh yes, now we are all waiting for news from the company (things take time) Patience!!! Do not take advice from others than yourself - regardless, it is YOUR responsibility if your invested kroner disappear. I myself have a lot to lose if this unexpectedly does not deliver. Recommend everyone to make up their own mind, the last place one should gather info is from private individuals who opine, speculate and recommend left and right. Of course there are some in here who are Seriously skilled, find new articles and share with us others who might not be as good at finding everything themselves - Thanks to you🙏 https://open.spotify.com/episode/6f9Hky8hlLABL7MC6QwAMB?si=kCnTlP_HSzOZ-DjNbsp52g&utm_source=copy-link
·1 t sitten"FENS 2026: Next-gen biologics take on brain disease. Whether it is by fine-tuning neurotransmitter signaling or dampening disease-associated genes, novel biological therapies are reshaping the development of neuroscience drugs, according to presentations at the FENS Forum 2026." (BioWorld, 9. juli 2026) FENS Forum 2026, which is being held in Barcelona this week (6.–10. juli), is Europe's largest and most important congress in neuroscience. The conference gathers over 7,000 international delegates – including top researchers, clinicians, academic institutions, and heavy business developers from the largest global pharmaceutical companies (Big Pharma). That "next-generation biological drugs" and advanced gene technology dominate this year's main presentations is a massive trend report for the sector. It confirms a fundamental shift away from traditional chemical medicines towards advanced biological tools for treating brain diseases. No competition, but a powerful catalyst This is by no means news about competitors threatening Circio's market. The presentations at the FENS congress concern companies and academic laboratories that map the disease mechanisms themselves – i.e., which specific genes or proteins must be targeted to slow down Alzheimer's, ALS, Parkinson's, or Huntington's. They develop the biological targets. They do not compete with Circio, which exclusively focuses on delivering the most effective transport mechanism to reach these targets. For a platform company, this congress acts as a powerful commercial catalyst: The more unique disease targets the industry discovers, the greater the acute need for an engine that can safely transport medicines into brain cells. Why is this important for Circio? For shareholders in Circio, the scientific momentum from this congress provides a direct commercial tailwind, especially related to three specific factors: 1. Circio's "hidden" CNS program hits the bullseye While the broad shareholder market today has its eyes fixed on the upcoming eye data (wet AMD), Circio has a very potent, but less profiled research program aimed precisely at CNS (central nervous system/brain). The company has already secured a strategic evaluation collaboration with a "top-5 global pharma-partner" in this segment. The first in vivo experiments (animal models) for this brain program are scheduled to land during the second half of 2026. This means that Circio delivers its first lab results into a market that is maximally heated. 2. Directly answers the industry's biggest headache: Duration As the presentations at FENS illustrate, modern neurological gene therapy is about delivering functional proteins or dampening harmful genes over a long period. However, ordinary, linear mRNA breaks down in the brain within a short time, which in the clinic would require frequent, risky, and costly injections into the spinal cord or brain of patients. Since circular RNA (circVec) is naturally resistant to biological degradation and has demonstrated up to 75 times longer half-life in cells than traditional RNA, Circio's engine solves the biological bottleneck this entire congress discusses: How to achieve lasting gene expression in the brain after only a single delivery. 3. Positioning for preclinical stage licensing agreements When thousands of researchers and pharma giants meet in Barcelona to showcase new target molecules, it confirms the structural pattern we see in the rest of the biotech market in the second half of 2026: Big Pharma has the capital and the targets, but they lack the genetic architecture. That the company has secured financing and operational stability in a long-term perspective means that management has the necessary patience to finalize undeniable and robust in vivo data for both the eye and CNS programs in the coming months. When the data is available, it will be presented to partners who are already fully convinced that the future of neurology belongs to biological RNA formats. Today's low pricing on the domestic stock exchange poorly reflects this global positioning.
·1 t sittenErik is super bullish here."I think everyone will eventually switch to circular RNA for applications where RNA is being used to express a therapeutic protein or antigen. There are some situations where it may not be applicable or may not be the best solution, but in the majority of therapeutic applications it is simply going to be so much better that people will have to make that transition." https://themedicinemaker.com/issues/2026/articles/july/inside-the-rise-of-circrna/
·3 t sittenGoodness, up a couple of øre, even after the closing auction 😉 A couple of important bullet points: - There will probably be such "boring days" with turnover around 15m +- going forward, as long as we don't get news from the company, or positive news in the media. Deal with it. Maybe a bit of Friday FOMO, but the price will soon hover relatively stable. - Others who think differently than you about the development or about the company are not necessarily idiots and clowns. OK? Fine. Everyone benefits from good tact and tone. - Some bought at a high price and are perhaps a bit nervous, which results in complaining and unserious posts. Bear with them. - There is no doubt that this is an exciting company. News can drive the price up, but there is no guarantee that it will happen next week, or in the near future. Do you believe in the case? Hold onto the shares. Don't you? Then you must consider selling. - Otherwise: enjoy the good weather ☀️
4 t sittenThey refuse to buy circio then panties they can fart on circio with 0.1% of their marketcap and we will get rich.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
85 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenDo YOU have a link to an interview with Wiklund or one of the others in the company? Or a podcast? Please post it below here. It would be nice to get a lot of information under 1 and the same post here. Good to listen more than 1 time. See many are angry and frustrated these days. Find information about the company that the management itself releases, there have been several interviews and podcasts shared previously....... oh yes, now we are all waiting for news from the company (things take time) Patience!!! Do not take advice from others than yourself - regardless, it is YOUR responsibility if your invested kroner disappear. I myself have a lot to lose if this unexpectedly does not deliver. Recommend everyone to make up their own mind, the last place one should gather info is from private individuals who opine, speculate and recommend left and right. Of course there are some in here who are Seriously skilled, find new articles and share with us others who might not be as good at finding everything themselves - Thanks to you🙏 https://open.spotify.com/episode/6f9Hky8hlLABL7MC6QwAMB?si=kCnTlP_HSzOZ-DjNbsp52g&utm_source=copy-link
- ·1 t sitten"FENS 2026: Next-gen biologics take on brain disease. Whether it is by fine-tuning neurotransmitter signaling or dampening disease-associated genes, novel biological therapies are reshaping the development of neuroscience drugs, according to presentations at the FENS Forum 2026." (BioWorld, 9. juli 2026) FENS Forum 2026, which is being held in Barcelona this week (6.–10. juli), is Europe's largest and most important congress in neuroscience. The conference gathers over 7,000 international delegates – including top researchers, clinicians, academic institutions, and heavy business developers from the largest global pharmaceutical companies (Big Pharma). That "next-generation biological drugs" and advanced gene technology dominate this year's main presentations is a massive trend report for the sector. It confirms a fundamental shift away from traditional chemical medicines towards advanced biological tools for treating brain diseases. No competition, but a powerful catalyst This is by no means news about competitors threatening Circio's market. The presentations at the FENS congress concern companies and academic laboratories that map the disease mechanisms themselves – i.e., which specific genes or proteins must be targeted to slow down Alzheimer's, ALS, Parkinson's, or Huntington's. They develop the biological targets. They do not compete with Circio, which exclusively focuses on delivering the most effective transport mechanism to reach these targets. For a platform company, this congress acts as a powerful commercial catalyst: The more unique disease targets the industry discovers, the greater the acute need for an engine that can safely transport medicines into brain cells. Why is this important for Circio? For shareholders in Circio, the scientific momentum from this congress provides a direct commercial tailwind, especially related to three specific factors: 1. Circio's "hidden" CNS program hits the bullseye While the broad shareholder market today has its eyes fixed on the upcoming eye data (wet AMD), Circio has a very potent, but less profiled research program aimed precisely at CNS (central nervous system/brain). The company has already secured a strategic evaluation collaboration with a "top-5 global pharma-partner" in this segment. The first in vivo experiments (animal models) for this brain program are scheduled to land during the second half of 2026. This means that Circio delivers its first lab results into a market that is maximally heated. 2. Directly answers the industry's biggest headache: Duration As the presentations at FENS illustrate, modern neurological gene therapy is about delivering functional proteins or dampening harmful genes over a long period. However, ordinary, linear mRNA breaks down in the brain within a short time, which in the clinic would require frequent, risky, and costly injections into the spinal cord or brain of patients. Since circular RNA (circVec) is naturally resistant to biological degradation and has demonstrated up to 75 times longer half-life in cells than traditional RNA, Circio's engine solves the biological bottleneck this entire congress discusses: How to achieve lasting gene expression in the brain after only a single delivery. 3. Positioning for preclinical stage licensing agreements When thousands of researchers and pharma giants meet in Barcelona to showcase new target molecules, it confirms the structural pattern we see in the rest of the biotech market in the second half of 2026: Big Pharma has the capital and the targets, but they lack the genetic architecture. That the company has secured financing and operational stability in a long-term perspective means that management has the necessary patience to finalize undeniable and robust in vivo data for both the eye and CNS programs in the coming months. When the data is available, it will be presented to partners who are already fully convinced that the future of neurology belongs to biological RNA formats. Today's low pricing on the domestic stock exchange poorly reflects this global positioning.
- ·1 t sittenErik is super bullish here."I think everyone will eventually switch to circular RNA for applications where RNA is being used to express a therapeutic protein or antigen. There are some situations where it may not be applicable or may not be the best solution, but in the majority of therapeutic applications it is simply going to be so much better that people will have to make that transition." https://themedicinemaker.com/issues/2026/articles/july/inside-the-rise-of-circrna/
- ·3 t sittenGoodness, up a couple of øre, even after the closing auction 😉 A couple of important bullet points: - There will probably be such "boring days" with turnover around 15m +- going forward, as long as we don't get news from the company, or positive news in the media. Deal with it. Maybe a bit of Friday FOMO, but the price will soon hover relatively stable. - Others who think differently than you about the development or about the company are not necessarily idiots and clowns. OK? Fine. Everyone benefits from good tact and tone. - Some bought at a high price and are perhaps a bit nervous, which results in complaining and unserious posts. Bear with them. - There is no doubt that this is an exciting company. News can drive the price up, but there is no guarantee that it will happen next week, or in the near future. Do you believe in the case? Hold onto the shares. Don't you? Then you must consider selling. - Otherwise: enjoy the good weather ☀️
- 4 t sittenThey refuse to buy circio then panties they can fart on circio with 0.1% of their marketcap and we will get rich.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
85 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenDo YOU have a link to an interview with Wiklund or one of the others in the company? Or a podcast? Please post it below here. It would be nice to get a lot of information under 1 and the same post here. Good to listen more than 1 time. See many are angry and frustrated these days. Find information about the company that the management itself releases, there have been several interviews and podcasts shared previously....... oh yes, now we are all waiting for news from the company (things take time) Patience!!! Do not take advice from others than yourself - regardless, it is YOUR responsibility if your invested kroner disappear. I myself have a lot to lose if this unexpectedly does not deliver. Recommend everyone to make up their own mind, the last place one should gather info is from private individuals who opine, speculate and recommend left and right. Of course there are some in here who are Seriously skilled, find new articles and share with us others who might not be as good at finding everything themselves - Thanks to you🙏 https://open.spotify.com/episode/6f9Hky8hlLABL7MC6QwAMB?si=kCnTlP_HSzOZ-DjNbsp52g&utm_source=copy-link
- ·1 t sitten"FENS 2026: Next-gen biologics take on brain disease. Whether it is by fine-tuning neurotransmitter signaling or dampening disease-associated genes, novel biological therapies are reshaping the development of neuroscience drugs, according to presentations at the FENS Forum 2026." (BioWorld, 9. juli 2026) FENS Forum 2026, which is being held in Barcelona this week (6.–10. juli), is Europe's largest and most important congress in neuroscience. The conference gathers over 7,000 international delegates – including top researchers, clinicians, academic institutions, and heavy business developers from the largest global pharmaceutical companies (Big Pharma). That "next-generation biological drugs" and advanced gene technology dominate this year's main presentations is a massive trend report for the sector. It confirms a fundamental shift away from traditional chemical medicines towards advanced biological tools for treating brain diseases. No competition, but a powerful catalyst This is by no means news about competitors threatening Circio's market. The presentations at the FENS congress concern companies and academic laboratories that map the disease mechanisms themselves – i.e., which specific genes or proteins must be targeted to slow down Alzheimer's, ALS, Parkinson's, or Huntington's. They develop the biological targets. They do not compete with Circio, which exclusively focuses on delivering the most effective transport mechanism to reach these targets. For a platform company, this congress acts as a powerful commercial catalyst: The more unique disease targets the industry discovers, the greater the acute need for an engine that can safely transport medicines into brain cells. Why is this important for Circio? For shareholders in Circio, the scientific momentum from this congress provides a direct commercial tailwind, especially related to three specific factors: 1. Circio's "hidden" CNS program hits the bullseye While the broad shareholder market today has its eyes fixed on the upcoming eye data (wet AMD), Circio has a very potent, but less profiled research program aimed precisely at CNS (central nervous system/brain). The company has already secured a strategic evaluation collaboration with a "top-5 global pharma-partner" in this segment. The first in vivo experiments (animal models) for this brain program are scheduled to land during the second half of 2026. This means that Circio delivers its first lab results into a market that is maximally heated. 2. Directly answers the industry's biggest headache: Duration As the presentations at FENS illustrate, modern neurological gene therapy is about delivering functional proteins or dampening harmful genes over a long period. However, ordinary, linear mRNA breaks down in the brain within a short time, which in the clinic would require frequent, risky, and costly injections into the spinal cord or brain of patients. Since circular RNA (circVec) is naturally resistant to biological degradation and has demonstrated up to 75 times longer half-life in cells than traditional RNA, Circio's engine solves the biological bottleneck this entire congress discusses: How to achieve lasting gene expression in the brain after only a single delivery. 3. Positioning for preclinical stage licensing agreements When thousands of researchers and pharma giants meet in Barcelona to showcase new target molecules, it confirms the structural pattern we see in the rest of the biotech market in the second half of 2026: Big Pharma has the capital and the targets, but they lack the genetic architecture. That the company has secured financing and operational stability in a long-term perspective means that management has the necessary patience to finalize undeniable and robust in vivo data for both the eye and CNS programs in the coming months. When the data is available, it will be presented to partners who are already fully convinced that the future of neurology belongs to biological RNA formats. Today's low pricing on the domestic stock exchange poorly reflects this global positioning.
- ·1 t sittenErik is super bullish here."I think everyone will eventually switch to circular RNA for applications where RNA is being used to express a therapeutic protein or antigen. There are some situations where it may not be applicable or may not be the best solution, but in the majority of therapeutic applications it is simply going to be so much better that people will have to make that transition." https://themedicinemaker.com/issues/2026/articles/july/inside-the-rise-of-circrna/
- ·3 t sittenGoodness, up a couple of øre, even after the closing auction 😉 A couple of important bullet points: - There will probably be such "boring days" with turnover around 15m +- going forward, as long as we don't get news from the company, or positive news in the media. Deal with it. Maybe a bit of Friday FOMO, but the price will soon hover relatively stable. - Others who think differently than you about the development or about the company are not necessarily idiots and clowns. OK? Fine. Everyone benefits from good tact and tone. - Some bought at a high price and are perhaps a bit nervous, which results in complaining and unserious posts. Bear with them. - There is no doubt that this is an exciting company. News can drive the price up, but there is no guarantee that it will happen next week, or in the near future. Do you believe in the case? Hold onto the shares. Don't you? Then you must consider selling. - Otherwise: enjoy the good weather ☀️
- 4 t sittenThey refuse to buy circio then panties they can fart on circio with 0.1% of their marketcap and we will get rich.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt